[go: up one dir, main page]

WO1999046574A3 - Anticorps permettant d'evaluer l'etat de modification post-translationnelle de proteine et procedes d'elaboration et d'utilisation correspondants - Google Patents

Anticorps permettant d'evaluer l'etat de modification post-translationnelle de proteine et procedes d'elaboration et d'utilisation correspondants Download PDF

Info

Publication number
WO1999046574A3
WO1999046574A3 PCT/US1999/004653 US9904653W WO9946574A3 WO 1999046574 A3 WO1999046574 A3 WO 1999046574A3 US 9904653 W US9904653 W US 9904653W WO 9946574 A3 WO9946574 A3 WO 9946574A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
making
methods
same
translational modification
Prior art date
Application number
PCT/US1999/004653
Other languages
English (en)
Other versions
WO1999046574A2 (fr
Inventor
Laszlo Otvos
Hildegund Ertl
Magdalena Thurin
Ralf Hoffman
Original Assignee
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst filed Critical Wistar Inst
Priority to AU30670/99A priority Critical patent/AU3067099A/en
Publication of WO1999046574A2 publication Critical patent/WO1999046574A2/fr
Publication of WO1999046574A3 publication Critical patent/WO1999046574A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé permettant d'élaborer des anticorps spécifiques pour les variants à modification post-translationnelle de la protéine p53. L'invention concerne également des anticorps polyclonaux et monoclonaux. L'invention concerne en outre un polypeptide utile dans l'élaboration de ces anticorps, qui comprend une partie de protéine à modification post-translationnelle, un espaceur peptidique et un activateur d'immunogénicité.
PCT/US1999/004653 1998-03-11 1999-03-11 Anticorps permettant d'evaluer l'etat de modification post-translationnelle de proteine et procedes d'elaboration et d'utilisation correspondants WO1999046574A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU30670/99A AU3067099A (en) 1998-03-11 1999-03-11 Antibodies for assessing protein post-translational modification status and methods of making and using the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7751298P 1998-03-11 1998-03-11
US60/077,512 1998-03-11

Publications (2)

Publication Number Publication Date
WO1999046574A2 WO1999046574A2 (fr) 1999-09-16
WO1999046574A3 true WO1999046574A3 (fr) 1999-10-21

Family

ID=22138511

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/004653 WO1999046574A2 (fr) 1998-03-11 1999-03-11 Anticorps permettant d'evaluer l'etat de modification post-translationnelle de proteine et procedes d'elaboration et d'utilisation correspondants

Country Status (2)

Country Link
AU (1) AU3067099A (fr)
WO (1) WO1999046574A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9110075B2 (en) 2001-05-21 2015-08-18 Monogram Biosciences, Inc. Compositions for analyzing proteins

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006106957A1 (ja) * 2005-04-01 2008-09-11 国立大学法人 北海道大学 ｐ５３翻訳後修飾部位を特異的に認識するモノクローナル抗体、及びその抗体を含む修飾部位測定キット

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
DAVIDOFF A. M., IGLEHART J. D., MARKS J. R.: "IMMUNE RESPONSE TO P53 IS DEPENDENT UPON P53/HSP70 COMPLEXES IN BREAST CANCERS.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 89., no. 08., 15 April 1992 (1992-04-15), US, pages 3439 - 3442., XP000602191, ISSN: 0027-8424, DOI: 10.1073/pnas.89.8.3439 *
GANNON J.V., ET AL.: "ACTIVATING MUTATIONS IN P53 PRODUCE A COMMON CONFORMATIONAL EFFECT.A MONOCLONAL ANTIBODY SPECIFIC FOR THE MUTANT FORM.", EMBO JOURNAL., OXFORD UNIVERSITY PRESS, SURREY., GB, vol. 09., no. 05., 1 March 1990 (1990-03-01), GB, pages 1595 - 1602., XP000676347, ISSN: 0261-4189 *
HAYES B K, HART G W: "NOVEL FORMS OF PROTEIN GLYCOSYLATION", CURRENT OPINION IN STRUCTURAL BIOLOGY, ELSEVIER LTD., GB, vol. 04, no. 05, 1 January 1994 (1994-01-01), GB, pages 692 - 696, XP002921586, ISSN: 0959-440X, DOI: 10.1016/S0959-440X(94)90167-8 *
JENKINS J R, ET AL.: "TWO DISTINCT REGIONS OF THE MURINE P53 PRIMARY AMINO ACID SEQUENCE ARE IMPLICATED IN STABLE COMPLEX FORMATION WITH SIMIAN VIRUS 40 T ANTIGEN", JOURNAL OF VIROLOGY., THE AMERICAN SOCIETY FOR MICROBIOLOGY., US, vol. 62, no. 10, 1 October 1988 (1988-10-01), US, pages 3903 - 3906, XP002921594, ISSN: 0022-538X *
LANG E, ET AL.: "IMMUNOLOGICAL AND CONFORMATIONAL CHARACTERIZATION OF A PHOSPHORYLATED IMMUNODOMINANT EPITOPE ON THE PAIRED HELICAL FILAMENTS FOUND IN ALZHEIMER'S DISEASE", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 187, no. 02, 16 September 1992 (1992-09-16), US, pages 783 - 790, XP002921588, ISSN: 0006-291X, DOI: 10.1016/0006-291X(92)91264-Q *
LEGROS Y., LAFON C., SOUSSI T.: "LINEAR ANTIGENIC SITES DEFINED BY THE B-CELL RESPONSE TO HUMAN P53 ARE LOCALIZED PREDOMINANTLY IN THE AMINO AND CARBOXY-TERMINI OFTHE PROTEIN.", ONCOGENE, NATURE PUBLISHING GROUP, GB, vol. 09., no. 07., 1 July 1994 (1994-07-01), GB, pages 2071 - 2076., XP002064622, ISSN: 0950-9232 *
LUBIN R, ET AL.: "ANALYSIS OF P53 ANTIBODIES IN PATIENTS WITH VARIOUS CANCERS DEFINE B-CELL EPITOPES OF HUMAN P53: DISTRIBUTION ON PRIMARY STRUCTURE ANDEXPOSURE ON PROTEIN SURFACE", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 53, 1 December 1993 (1993-12-01), US, pages 5872 - 5876, XP002921592, ISSN: 0008-5472 *
MILCZAREK G J, MARTINEZ J, BOWDEN G T: "P53 PHOSPHORYLATION: BIOCHEMICAL AND FUNCTIONAL CONSEQUENCES", LIFE SCIENCES., PERGAMON PRESS, OXFORD, GB, vol. 60, no. 01, 1 January 1997 (1997-01-01), GB, pages 01 - 11, XP002921593, ISSN: 0024-3205, DOI: 10.1016/S0024-3205(96)00479-1 *
MILNER J, MEDCALF E A, COOK A C: "TUMOR SUPPRESSOR P53: ANALYSIS OF WILD-TYPE AND MUTANT P53 COMPLEXES", MOLECULAR AND CELLULAR BIOLOGY., AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON., US, vol. 11, no. 01, 1 January 1991 (1991-01-01), US, pages 12 - 19, XP002921590, ISSN: 0270-7306 *
MILNER J: "FORMS AND FUNCTIONS OF P53", SEMINARS IN CANCER BIOLOGY., SAUNDERS SCIENTIFIC PUBLICATIONS, PHILADELPHIA, PA., US, vol. 05, 1 January 1994 (1994-01-01), US, pages 211 - 219, XP002921589, ISSN: 1044-579X *
SCHREINER R, SCHNABEL E, WIELAND F: "NOVEL N-GLYCOSYLATION IN EUKARYOTES: LAMININ CONTAINS THE LINKAGE UNIT BETA-GLUCOSYLASPARAGINE", THE JOURNAL OF CELL BIOLOGY : JCB, THE ROCKEFELLER UNIVERSITY PRESS, US, vol. 124, no. 06, 1 March 1994 (1994-03-01), US, pages 1071 - 1081, XP002921587, ISSN: 0021-9525, DOI: 10.1083/jcb.124.6.1071 *
SHAW P., ET AL.: "REGULATION OF SPECIFIC DNA BINDING BY P53: EVIDENCE FOR A ROLE FOR O-GLYCOSYLATION AND CHARGED RESIDUES AT THE CARBOXY-TERMINUS.", ONCOGENE, NATURE PUBLISHING GROUP, GB, vol. 12., 15 February 1996 (1996-02-15), GB, pages 921 - 930., XP000569573, ISSN: 0950-9232 *
STEEGENGA W T, EB VAN DER A J, JOCHEMSEN A G: "HOW PHOSPHORYLATION REGULATION THE ACTIVITY OF P53", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 263, 1 January 1996 (1996-01-01), United Kingdom, pages 103 - 113, XP002921585, ISSN: 0022-2836, DOI: 10.1006/jmbi.1996.0560 *
TAKENAKA I., ET AL.: "REGULATION OF THE SEQUENCE-SPECIFIC DNA BINDING FUNCTION OF P53 BY PROTEIN KINASE C AND PROTEIN PHOSPHATASES.", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 270., no. 10., 10 March 1995 (1995-03-10), US, pages 5405 - 5411., XP002003076, ISSN: 0021-9258, DOI: 10.1074/jbc.270.10.5405 *
VOJTESEK B, ET AL.: "AN IMMUNOCHEMICAL ANALYSIS OF THE HUMAN NUCLEAR PHOSPHOPROTEIN P53", JOURNAL OF IMMUNOLOGICAL METHODS., ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM., NL, vol. 151, 1 January 1992 (1992-01-01), NL, pages 237 - 244, XP002921591, ISSN: 0022-1759, DOI: 10.1016/0022-1759(92)90122-A *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9110075B2 (en) 2001-05-21 2015-08-18 Monogram Biosciences, Inc. Compositions for analyzing proteins

Also Published As

Publication number Publication date
WO1999046574A2 (fr) 1999-09-16
AU3067099A (en) 1999-09-27

Similar Documents

Publication Publication Date Title
BR9810654B8 (pt) mÉtodo de preparaÇço de um polipeptÍdeo, molÉculas de anticorpo e composiÇço.
HK1049184A1 (zh) 具有增强抗凝血效能的抗组织因子抗体
WO2001087919A3 (fr) Methodes permettant de detecter des interactions entre des proteines, des peptides ou leurs bibliotheques au moyen de proteines de fusion
WO2003029458A3 (fr) Procede pour produire des banques de proteines et selectionner des proteines a partir de ces banques
WO1999020756A3 (fr) Homologues toll humains
EP0960939A3 (fr) Protéines doublemment étiquettées et leurs utilisations
WO2001058956A3 (fr) Anticorps de liaison de l'interleukine 18 humaine et procedes de preparation et d'utilisation
EP2248899B8 (fr) Protéine de liaison du récepteur NOGO
EP1439193A3 (fr) Anticorps contre la heparanase
WO1999003987A3 (fr) Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
WO2001004265A3 (fr) Marquage de proteines c-terminales
WO2001049713A3 (fr) Peptides stabilisants, polypeptides et anticorps les contenant
WO1995014778A3 (fr) Sequence d'adn codant pour un recepteur de la proteine morphogenetique osseuse
AU2001276916A1 (en) Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
AU2002217212A1 (en) Method for preparing a human monoclonal antibody, fragments thereof or antibodies comprising such fragments, resulting antibodies and use thereof
WO1999046574A3 (fr) Anticorps permettant d'evaluer l'etat de modification post-translationnelle de proteine et procedes d'elaboration et d'utilisation correspondants
WO2002088315A3 (fr) Vecteurs phagemides
WO2004020588A3 (fr) Banques de proteines de fusion de la transferine
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
AU3070399A (en) Method of detecting axonal damage, associated disease states, and related monoclonal antibodies and protein controls therefor
EP0879879A3 (fr) Polypeptide déformylase 1 (Def1)
CA2194032A1 (fr) Sequence d'adn fusionnee, proteine fusionnee exprimee par ladite sequence d'adn et methode d'expression de ladite proteine fusionnee
EP0911409A3 (fr) Deformylase
WO2002056236A3 (fr) Classification de polypeptides par geometrie des ligands et procedes associes
EP0816498A3 (fr) Récepteur pour acide aminé excitateur et acides nucléiques liés

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase